ARS Pharmaceuticals Inc (NASDAQ: SPRY) is 21.33% higher on its value in year-to-date trading and has touched a low of $7.55 and a high of $18.51 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The SPRY stock was last observed hovering at around $13.40 in the last trading session, with the day’s loss setting it -0.6%.
Currently trading at $12.80, the stock is 3.27% and 5.54% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.8 million and changing -4.48% at the moment leaves the stock 2.57% off its SMA200. SPRY registered 36.17% gain for a year compared to 6-month loss of -11.42%. The firm has a 50-day simple moving average (SMA 50) of $12.1278 and a 200-day simple moving average (SMA200) of $12.478775.
The stock witnessed a 18.63% gain in the last 1 month and extending the period to 3 months gives it a 19.51%, and is 2.48% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.02% over the week and 7.56% over the month.
ARS Pharmaceuticals Inc (SPRY) has around 160 employees, a market worth around $1.26B and $89.15M in sales. Current P/E ratio is 166.88. Profit margin for the company is 8.97%. Distance from 52-week low is 69.54% and -30.85% from its 52-week high. The company has generated returns on investments over the last 12 months (3.11%).
with sales reaching $7.48M over the same period.The EPS is expected to shrink by -1764.10% this year, but quarterly earnings will post -6.80% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
ARS Pharmaceuticals Inc (SPRY) Top Institutional Holders
230.0 institutions hold shares in ARS Pharmaceuticals Inc (SPRY), with institutional investors hold 97.25% of the company’s shares. The shares outstanding are 97.95M, and float is at 56.04M with Short Float at 34.67%. Institutions hold 74.91% of the Float.
The top institutional shareholder in the company is DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) with over 11.08 million shares valued at $94.27 million. The investor’s holdings represent 11.4409% of the SPRY Shares outstanding. As of 2024-06-30, the second largest holder is RA CAPITAL MANAGEMENT, L.P. with 10.86 million shares valued at $92.43 million to account for 11.2168 of the shares outstanding. The other top investors are ORBIMED ADVISORS LLC which holds 9.24 million shares representing 9.5436% and valued at over $78.64 million, while BLACKROCK INC. holds 4.2182 of the shares totaling 4.08 million with a market value of $34.76 million.
ARS Pharmaceuticals Inc (SPRY) Insider Activity
The most recent transaction is an insider sale by Karas Eric, the company’s Chief Commercial Officer. SEC filings show that Karas Eric sold 10,000 shares of the company’s common stock on Mar 20 ’25 at a price of $14.00 per share for a total of $0.14 million. Following the sale, the insider now owns 7696.0 shares.
Still, SEC filings show that on Mar 06 ’25, Shawver Laura (Director) disposed off 49,600 shares at an average price of $11.21 for $0.56 million. The insider now directly holds 210,346 shares of ARS Pharmaceuticals Inc (SPRY).
